This is what Americans voted for!
President Donald Trump announced Friday that his administration has secured major new agreements with some of the world’s largest pharmaceutical companies—marking a significant step toward lowering prescription drug costs for American patients, seniors, and taxpayers.
Speaking from the Roosevelt Room, President Trump announced that nine more international drugmakers have signed onto the administration’s most-favored-nation pricing policy, bringing participation to 14 of the world’s 17 largest pharmaceutical companies.
The agreements go beyond pricing. According to the administration, participating companies have pledged more than $150 billion in new investments toward U.S.-based pharmaceutical manufacturing, research, and development—bringing jobs, innovation, and supply-chain security back to America.
“For the American people and for patients, this is a major victory for affordability,” Trump said. “Americans should not be paying far more than other countries for the same medicines.”
Major Drug Companies Join the Deal
The newly announced agreements include some of the biggest names in the pharmaceutical industry, including Amgen, Merck, Novartis, Sanofi, GSK, Bristol-Myers Squibb, Gilead, Genentech, and Boehringer Ingelheim.
The deals follow letters Trump sent earlier this year to the leaders of the 17 largest drug manufacturers, urging them to reduce prices for Americans enrolled in Medicaid and to end the long-standing practice of charging U.S. patients more than those in other wealthy nations.
Lower Costs, Stronger National Security
Several companies involved in the agreements have also committed to donating active pharmaceutical ingredients to the nation’s Strategic Active Pharmaceutical Ingredients Reserve, strengthening America’s readiness for future pandemics, natural disasters, or national security emergencies.
“This is also about national security,” Trump said. “You cannot depend on foreign supply chains while charging Americans the highest prices in the world.”
Previously, companies such as Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly had already signed similar agreements with the Trump administration aimed at keeping prescription drugs affordable for lower-income Americans.
A Promise Kept After Decades of Talk
Reducing prescription drug prices has long been a political talking point in Washington. Presidents from both parties made promises—but delivered limited results.
Trump emphasized that his approach directly addresses the pricing imbalance that has burdened American seniors and families for decades.
“Other presidents talked about it,” Trump said. “We actually did it. America is finally being treated fairly.”
The administration noted that Medicaid, which accounts for a significant share of U.S. prescription drug spending, will see meaningful long-term savings under the new framework.
HHS Calls Deal Historic
Health and Human Services Secretary Robert F. Kennedy Jr. described the agreements as historic, noting that similar ideas had been promoted by prominent Democrats for years without success.
“Everyone knew the system was unfair,” Kennedy said. “Americans were paying for innovation while other countries benefited. This administration corrected that imbalance.”
Kennedy added that by the end of Trump’s term, Americans are projected to pay some of the lowest prescription drug prices in the world for the vast majority of medications—an outcome he said no prior administration achieved.
New Tool for Patients Coming Soon
Trump also announced the upcoming launch of TrumpRX.gov, a new federal website designed to help Americans access lower-cost prescription medications and pricing information. The site is expected to go live in January 2026, according to a notice currently posted online.
For millions of seniors, retirees, and working families—many living on fixed incomes—the announcement represents more than policy. It signals relief after years of rising healthcare costs and broken promises.
Once again, supporters say, President Trump delivered results where Washington had long failed.